Literature DB >> 18591460

Serotonin 5-HT(2B) receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice.

Laurent Monassier1, Marc-André Laplante, Fabrice Jaffré, Pascal Bousquet, Luc Maroteaux, Jacques de Champlain.   

Abstract

We established previously that 5-HT(2B) receptors are involved in cardiac hypertrophy through the regulation of hypertrophic cytokines in cardiac fibroblasts. Moreover, the generation of reactive oxygen species and tumor necrosis factor-alpha through the activation of reduced nicotinamide-adenine dinucleotide phosphate [NAD(P)H] oxidase has been implicated in cardiac hypertrophy. In this study, we investigated whether 5-HT(2B) receptors could be involved in the development of cardiac hypertrophy associated with superoxide anion production. Therefore, we measured the effects of serotonergic 5-HT(2B) receptor blockade on left-ventricular superoxide anion generation in 2 established pharmacological models of cardiac hypertrophy, ie, angiotensin II and isoproterenol infusions in mice. Angiotensin II infusion for 14 days increased superoxide anion concentration (+32%), NAD(P)H oxidase maximal activity (+84%), and p47(phox) NAD(P)H oxidase subunit expression in the left ventricle together with hypertension (+37 mm Hg) and cardiac hypertrophy (+17% for heart weight:body weight). The 5-HT(2B) receptor blockade by a selective antagonist (SB215505) prevented the increase in cardiac superoxide generation and hypertrophy. Similarly, infusion for 5 days of isoproterenol increased left-ventricular NAD(P)H oxidase activity (+48%) and cardiac hypertrophy (+31%) that were prevented by the 5-HT(2B) receptor blockade. Finally, in the primary culture of left-ventricular cardiac fibroblasts, angiotensin II and isoproterenol stimulated NAD(P)H oxidase activity. This activation was prevented by SB215505. These findings suggest that the 5-HT(2B) receptor may represent a new target to reduce cardiac hypertrophy and oxidative stress. Its blockade affects both angiotensin II and beta-adrenergic trophic responses without significant hemodynamic alteration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18591460     DOI: 10.1161/HYPERTENSIONAHA.107.105551

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  12 in total

Review 1.  Serotonin receptors and heart valve disease--it was meant 2B.

Authors:  Joshua D Hutcheson; Vincent Setola; Bryan L Roth; W David Merryman
Journal:  Pharmacol Ther       Date:  2011-04-02       Impact factor: 12.310

2.  Role of serotonin 5-HT2A receptors in the development of cardiac hypertrophy in response to aortic constriction in mice.

Authors:  O Lairez; T Cognet; S Schaak; D Calise; C Guilbeau-Frugier; A Parini; J Mialet-Perez
Journal:  J Neural Transm (Vienna)       Date:  2013-03-30       Impact factor: 3.575

3.  Serotonin 2A and 2B receptor-induced phrenic motor facilitation: differential requirement for spinal NADPH oxidase activity.

Authors:  P M MacFarlane; S Vinit; G S Mitchell
Journal:  Neuroscience       Date:  2011-01-09       Impact factor: 3.590

4.  Involvement of Depressive Catecholamines as Thrombosis Risk/Inflammatory Markers in Non-Smoker, Non-Obese Congestive Heart Failure, Linked to Increased Epidermal Growth Factor-Receptor (EGF-R) Production.

Authors:  Nadia M Hamdy; Lamiaa El-Wakeel; Salwa M Suwailem
Journal:  Indian J Clin Biochem       Date:  2011-01-13

5.  Serotonin and catecholamines in the development and progression of heart valve diseases.

Authors:  Elliott Goldberg; Juan B Grau; Jacqueline H Fortier; Elisa Salvati; Robert J Levy; Giovanni Ferrari
Journal:  Cardiovasc Res       Date:  2017-07-01       Impact factor: 10.787

Review 6.  G-Protein-Coupled Receptors in Heart Disease.

Authors:  Jialu Wang; Clarice Gareri; Howard A Rockman
Journal:  Circ Res       Date:  2018-08-31       Impact factor: 17.367

Review 7.  Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties.

Authors:  B Guardiola-Lemaitre; C De Bodinat; P Delagrange; M J Millan; C Munoz; E Mocaër
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

8.  Cellular Interplay between Cardiomyocytes and Nonmyocytes in Cardiac Remodeling.

Authors:  Norifumi Takeda; Ichiro Manabe
Journal:  Int J Inflam       Date:  2011-09-18

9.  5-HT2B receptor antagonists inhibit fibrosis and protect from RV heart failure.

Authors:  Wiebke Janssen; Yves Schymura; Tatyana Novoyatleva; Baktybek Kojonazarov; Mario Boehm; Astrid Wietelmann; Himal Luitel; Kirsten Murmann; Damian Richard Krompiec; Aleksandra Tretyn; Soni Savai Pullamsetti; Norbert Weissmann; Werner Seeger; Hossein Ardeschir Ghofrani; Ralph Theo Schermuly
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

Review 10.  Serotonin paracrine signaling in tissue fibrosis.

Authors:  Derek A Mann; Fiona Oakley
Journal:  Biochim Biophys Acta       Date:  2012-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.